Sacubitril And Valsartan Tablet
Product Images NDC 70710-1272

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Sacubitril And Valsartan (NDC 70710-1272). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Zydus Pharmaceuticals Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (5ac80900 51d2 40f9 B897 Df34ace38cfe 01)

Chemical structure diagram showing the molecular components of sacubitril and valsartan, including hydrate and sodium salt notations. The structure depicts the active ingredients represented in the product sacubitril and valsartan tablets by Zydus Pharmaceuticals USA Inc.*

FDA Label Image

Image (5ac80900 51d2 40f9 B897 Df34ace38cfe 02)

A chart illustrating the geometric mean ratio and 90% confidence intervals for coadministered drugs relative to reference values. It compares changes in area under the curve (AUC) and peak concentration (Cmax) for drugs including furosemide, warfarin, digoxin, carvedilol, levonorgestrel, ethinyl estradiol, amlodipine, HCTZ, metformin, atorvastatin, and sildenafil.*

FDA Label Image

Image (5ac80900 51d2 40f9 B897 Df34ace38cfe 03)

A forest plot chart showing geometric mean ratios and 90% confidence intervals for AUC and Cmax of sacubitril and valsartan across various population subgroups, including renal impairment levels, hepatic impairment, age groups, sex, and racial groups, relative to a reference standard.*

FDA Label Image

Image (5ac80900 51d2 40f9 B897 Df34ace38cfe 04)

Three Kaplan-Meier curve graphs showing clinical outcomes comparing sacubitril and valsartan versus enalapril in the PARADIGM-HF study. Figure A displays time to first occurrence of cardiovascular death or heart failure hospitalizations; Figure B shows time to occurrence of cardiovascular death; Figure C presents time to first heart failure hospitalizations. Each graph includes hazard ratio estimates and patient risk counts over time.*

FDA Label Image

Image (5ac80900 51d2 40f9 B897 Df34ace38cfe 05)

A forest plot comparing the hazard ratios of sacubitril and valsartan versus enalapril across various patient subgroups. Subgroups include age, gender, weight, race, region, NYHA class, estimated GFR, diabetes status, systolic blood pressure, ejection fraction, atrial fibrillation, NT-proBNP levels, hypertension, prior use of ACE inhibitors, ARBs, aldosterone antagonists, prior hospitalization for heart failure, time since diagnosis, cause of heart failure, and presence of ICD. The plot shows data points with confidence intervals indicating relative risk between the two medications.*

FDA Label Image

Fig 5 (5ac80900 51d2 40f9 B897 Df34ace38cfe 06)

A line graph illustrating total heart failure hospitalization and cardiovascular (CV) death in the PARAGON-HF study comparing sacubitril and valsartan versus valsartan alone. The x-axis represents time since randomization in days, ranging from 0 to 1440, and the y-axis shows the mean number of events per 100 patients, ranging from 0 to 60. Two lines indicate that patients treated with sacubitril and valsartan had fewer events over time compared to those treated with valsartan alone. A table below the graph reports the number of patients at risk at various time points for both treatment groups.*

FDA Label Image

Fig 6 (5ac80900 51d2 40f9 B897 Df34ace38cfe 07)

A forest plot comparing the rate ratios of sacubitril and valsartan versus valsartan alone across various subgroups such as age, gender, race, region, diabetic status, left ventricular ejection fraction (LVEF), atrial fibrillation (AF) status, NT-proBNP levels, and others. The plot displays confidence intervals and rate ratios indicating relative performance, with points distributed along a scale where values less than one favor sacubitril and valsartan.*

FDA Label Image

Fig 7 (5ac80900 51d2 40f9 B897 Df34ace38cfe 08)

A line chart depicting hazard ratios and 95% confidence intervals from the PARAGON-HF study comparing sacubitril and valsartan versus enalapril and versus valsartan. The x-axis shows left ventricular ejection fraction at screening (%) ranging from 0 to 75, while the y-axis shows hazard ratio values ranging from 0.5 to 16. Two graphs compare treatment effects with hazard ratios and confidence intervals displayed as solid and dashed lines, respectively.*

FDA Label Image

Image (5ac80900 51d2 40f9 B897 Df34ace38cfe 09)

Label for sacubitril and valsartan tablets, showing strength 24 mg sacubitril and 26 mg valsartan. The oral tablet comes in a package of 60 tablets. The label includes manufacturer information, Zydus Lifesciences Ltd., and distributor Zydus Pharmaceuticals (USA) Inc. The label measurement is 95 mm by 41 mm and includes storage instructions and a barcode.*

FDA Label Image

Image (5ac80900 51d2 40f9 B897 Df34ace38cfe 10)

Sacubitril and Valsartan Tablets packaging label showing the strength of 49 mg/51 mg per tablet. The label indicates the package contains 60 tablets and is marked for prescription use only. It includes storage instructions, manufacturer Zydus Lifesciences Ltd. in India, and distributor Zydus Pharmaceuticals USA Inc. in New Jersey. The package is child-resistant and includes an NDC code 70710-1273-6.*

FDA Label Image

Image (5ac80900 51d2 40f9 B897 Df34ace38cfe 11)

Label for sacubitril and valsartan tablets 97 mg/103 mg oral dosage form, manufactured by Zydus Lifesciences Ltd. and distributed by Zydus Pharmaceuticals (USA) Inc. The label indicates a package of 60 film-coated tablets, with storage instructions and manufacturer details, including the NDC code 70710-1274-6.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.